IMU - Broker Data, page-196

That was the confidence shown by her in terms of "billion dollar" call, I understand India and China patent protection will not lead to anything substantial until and unless FDA approves the drug, may be clinical trail sites will be established in these countries and target population required for clinical trial conclusion can be realized in India and China while making sure they do not copy on the backdrop of clinical trials and produce their own , I am looking this as incoming news about phase 2/phase 3 clinical trials in this population as they require large cohorts..